Posts
- Calidi Biotherapeutics Announces IL15 Superagonist as First Payload to be Delivered by Systemic Antitumor Virotherapy Platform at AACR Annual Meeting
- Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711
- Calidi Biotherapeutics Announces Chief Executive Officer Transition and Appointment of Eric Poma, Ph.D. as CEO and Director
- Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24
- Calidi Biotherapeutics Announces FDA Clearance of IND Application for CLD-201 in Solid Tumors
- Calidi Biotherapeutics Announces Appointment of Guy Travis Clifton, MD as Chief Medical Officer, Consultant and Advisor
- Calidi Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private Placement
- Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational Highlights
- Calidi Biotherapeutics Announces Pricing of $3.9 Million Registered Direct Offering and Concurrent Private Placement
- Calidi Biotherapeutics and City of Hope Provide Update on a Phase 1 Clinical Trial with CLD-101 Virotherapy in Patients with Recurrent High-Grade Glioma
- Calidi Biotherapeutics Announces Demonstrated Ability To Deliver Transient Gene Therapy (Payload) To Tumors Using Systemic Platform
- Calidi Biotherapeutics Announces Commencement of Recruitment for Multiple Dose CLD-101 Trial in Patients with Newly Diagnosed High Grade Glioma at Northwestern University Hospital
- Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on February 5
- Calidi Biotherapeutics Announces Bolstered Cash Balance and Termination of its Standby Equity Purchase Agreement
- Calidi Biotherapeutics Announces Presentation of New Data of Systemic Virotherapy RTNova Platform at the AACR Annual Meeting in April 2025
- Calidi Biotherapeutics Announces Pricing of $4.25 Million Public Offering of Common Stock
- Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock
- Calidi Biotherapeutics Announces Proposed Public Offering
- Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer
- Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock
- Calidi Biotherapeutics Announces Pricing of $7.5 Million Public Offering of Common Stock
- Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results
- Calidi Biotherapeutics to Present Data Supporting RTNova at Upcoming Scientific Conferences
- Calidi Biotherapeutics Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement
- Calidi Biotherapeutics Announces FDA Clearance of the Northwestern University IND Application for CLD-101 Clinical Trial in High-Grade Glioma
- Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results
- Calidi Biotherapeutics Announces Launch of Nova Cell Subsidiary and $3 Million Aggregate Investment from Dr. Ronald Rigor
- Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform
- Calidi Biotherapeutics Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board
- Calidi to Effect Reverse Stock Split
- Calidi Biotherapeutics Announces Appointment of Cancer Immunotherapy Pioneer Dr. George Peoples to Board of Directors
- Calidi Biotherapeutics to Host Exclusive Live Investor Webinar and Q&A Session on June 13
- Calidi Biotherapeutics Collaborates with SIGA Technologies to Advance Calidi’s Revolutionary RTNova Virotherapy for Lung Cancer and Metastatic Solid Tumors
- Calidi Biotherapeutics Presents CLD-101 Phase 1 Trial Update and Preclinical Data Highlighting RTNova and CLD-201 at 2024 ASCO Annual Meeting
- Calidi Biotherapeutics Announces Exercise of Warrants for $2.1 Million Gross Proceeds
- Calidi Biotherapeutics Reports First Quarter 2024 Operating and Financial Results
- Calidi Biotherapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting
- Calidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public Offering
- Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public Offering
- Calidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company’s Novel Immunotherapies at the AACR Annual Meeting 2024
- Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine (CIRM) to Advance CLD-101 (NeuroNova) in Ovarian Cancer
- Calidi Biotherapeutics to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform Designed to Target All Tumor Sites at Upcoming Conference
- Calidi Biotherapeutics Announces the Appointment of Three New Members to its Scientific and Medical Advisory Board
- Calidi Biotherapeutics Announces Presentation of Clinical Study for NeuroNova with Recurrent High Grade Glioma at the 8th Oncolytic Virotherapy Summit
- Calidi Biotherapeutics Announces Appointment of Pharmaceutical Industry Veteran David LaPré to its Board of Directors
- Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform and Updates Anticipated Clinical Milestones
- Calidi Biotherapeutics Reports Third Quarter 2023 Operating and Financial Result
- Calidi Biotherapeutics (NYSEAM: CLDI) Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC 2023)
- Calidi Biotherapeutics Announces Key Leadership Promotions and New Board Appointment
- Calidi Biotherapeutics Announces Appointment of Andrew Jackson as Chief Financial Officer
- Calidi Biotherapeutics To Present New Preclinical Data Highlighting Cell-based Virotherapy (SuperNova) Platform Technology at SITC 2023
- Calidi Biotherapeutics Debuts as a Publicly Traded Company Focused on Arming the Immune System to Fight Cancer with a New Generation of Targeted Immunotherapies
- Calidi Biotherapeutics to Present at Baird’s Global Healthcare Conference
- Calidi Biotherapeutics and City of Hope announce first patient dosed in a Phase 1 clinical trial evaluating neural stem cells engineered to carry an oncolytic virus, CLD-101, in recurrent high-grade glioma patients
- Calidi Biotherapeutics Announces Commitment of $25 Million in Series B Funding to Advance Stem Cell-Based Platforms for the Delivery and Potentiation of Oncolytic Viruses to Treat Cancer
- Calidi Biotherapeutics and First Light Acquisition Group (FLAG) Announce Merger Agreement to Create a Publicly Listed, Clinical-Stage Biotechnology Company Utilizing Stem Cell-Based Platforms to Revolutionize Oncolytic Virotherapies
- Calidi Biotherapeutics Receives Funding from the California Institute for Regenerative Medicine (CIRM) to Advance SuperNova-1 and NeuroNova-2 Development Programs
- Calidi Biotherapeutics to Present at the 7th Annual Oncolytic Virotherapy Summit
- Calidi Biotherapeutics Presents Promising Pre-Clinical Data from SuperNova-1 (SNV1), a Novel Oncolytic-Cell Based Platform, at the Society for Immunotherapy of Cancer’s 37th Annual Meeting (SITC 2022)
- Calidi Biotherapeutics to Present Pre-Clinical SuperNova1 (SNV1) Data at the 2022 SITC Annual Meeting
- Calidi Biotherapeutics Appoints David Sans, FAARM, Ph.D., MBA, as Head of Corporate Development
- Calidi Biotherapeutics to Present at Two Upcoming Conferences
- Calidi Biotherapeutics Announces FDA Authorization of IND for a Phase 1 Clinical Trial of NeuroNova in Patients with Recurrent High-Grade Glioma
- Calidi Biotherapeutics Announces Appointment of W.K. Alfred Yung, M.D., to its Medical Advisory Board
- Calidi Biotherapeutics to Present at Jefferies Healthcare Conference
- Calidi Biotherapeutics Granted US Patent for Proprietary Therapeutic Delivery Platform, Strengthening Company’s Intellectual Property Position in Immunotherapy
- Calidi Biotherapeutics Announces Appointment of Alfonso “Chito” Zulueta, Former President of International for Eli Lilly, to Its Board of Directors
- Calidi Biotherapeutics and Edoc Acquisition Corp. Agree to Merge and Create a Publicly Listed, Clinical-Stage Biotechnology Company Utilizing Stem Cell-Based Platforms to Revolutionize Oncolytic Virotherapies
- Calidi Biotherapeutics Announces Dr. Maciej S. Lesniak Presentation at 13th International Oncolytic Virotherapy Conference
- Calidi Biotherapeutics Announces Presentation at 6th Annual Oncolytic Virotherapy Summit
- Calidi Biotherapeutics Announces Exclusive License Agreement with City of Hope and the University of Chicago for Novel Oncolytic Virotherapy Technology
- Calidi Biotherapeutics Announces Agreement with Northwestern University for Exclusive Commercial Rights to their IND for Treatment of Malignant Glioma
- Calidi Biotherapeutics Announces Partnership with GenScript ProBio for Distribution of its SuperNova-1 Technology
- Calidi Biotherapeutics Announces European Patent Granted by EPO: Combination Immunotherapy Approach for Treatment of Cancer
- Calidi Biotherapeutics Announces FDA Approval for COVID-19 Treatment Manufactured by Partner, Personalized Stem Cells
- Calidi Biotherapeutics Announces Appointment of Jim Schoeneck, Accomplished Biotech Executive, to Board of Directors
- Calidi Biotherapeutics Announces Two Abstracts Accepted for Presentation at AACR 2020 Virtual Annual Meeting II
- Stem Cells for COVID-19 | PSC Teams Up with Calidi Biotherapeutics
- Calidi Biotherapeutics Announces Appointment of Dr. George Peoples, a Prominent Immuno-Oncology Expert, to its Scientific and Medical Advisory Board
- Calidi Biotherapeutics Announces Appointment of Biotech Veteran Heehyoung Lee to Board of Directors
- Calidi Biotherapeutics Presents Data at the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium
- Calidi Biotherapeutics Announces Abstract Acceptance For Presentation at the ASCO-SITC Clinical Immuno-Oncology Symposium
- Calidi Biotherapeutics Secures Series A Investments to Advance Manufacturing
- The Mitchell Thorp Foundation Selects Calidi Biotherapeutics CEO to Receive the Pillars of Hope Award
- Calidi Biotherapeutics Announces Appointment of Seasoned Biotech Executive George Ng to Board of Directors
- Calidi Biotherapeutics Named One of the “50 Most Trustworthy Companies of The Year 2019” by the Silicon Review Magazine
- Calidi Biotherapeutics is initiating GMP manufacturing at VetStem BioPharma, a veterinary and human regenerative medicine company in San Diego, CA
- Calidi Biotherapeutics Announces the Appointment of Distinguished Biotech Innovator, Ewa Carrier, M.D., to Their Medical and Scientific Advisory Board
- Calidi Biotherapeutics Announces Global Oncolytic Virus-based Immunotherapy License to VetStem Biopharma for its Pioneering Treatment of Cancer in the Veterinary Field
- Calidi Biotherapeutics Announces The Appointment of Medical Oncologist and Expert in Oncolytic Immunotherapies, Dr. Dmitriy Zamarin to Their Scientific Advisory Board
- Calidi Biotherapeutics Announces The Appointment Of Seasoned Biotech Executive Dr. Ashok Srivastava To Their Scientific Advisory Board
- Calidi Biotherapeutics Announces A Collaborative Study With The National Institutes Of Health (NIH) On The Therapeutic Potential Of Oncolytic Viruses Delivered By Mesenchymal Stem Cells
- Calidi Biotherapeutics Releases Recent Interviews of CEO Allan Camaisa
- Calidi Biotherapeutics Launches Scientific and Medical Advisory Board
- Calidi Biotherapeutics, Inc. announces its corporate vision in groundbreaking cancer drug development and appoints Allan Camaisa as CEO
- Calidi Biotherapeutics Announces Two Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting
- Calidi Biotherapeutics, Inc. Granted New Patent from USPTO for Cell-Based Delivery Of Oncolytic Vaccinia Viruses
Team Members
- Eric Poma, Ph.D.
- Andrew Jackson
- Antonio F. Santidrian, PharmD, Ph.D.
- Guy Travis Clifton, M.D.
- Boris Minev, M.D.
- Wendy Pizarro, Esq.
- Karen Aboody, M.D.
- Ewa Carrier, M.D.
- Santosh Kesari, M.D., Ph.D.
- Matt S. Lesniak, M.D.
- Ashok Srivastava, M.D., Ph.D.
- W.K. Alfred Yung, M.D.
- Dmitriy Zamarin, M.D., Ph.D.
- Mark Gilbert M.D.
- L. Burt Nabors, M.D.
- Dr. E. Antonio Chiocca
- David T Curiel, M.D., Ph.D.
- James A. Schoeneck
- George E. Peoples, M.D., FACS
- Scott Leftwich
- Allan Camaisa
- Alan Stewart
- Eric Poma, Ph.D.
